SUPERNUS PHARMACEUTICALS, INC.
SUPNNext catalyst
BIS-001ER
Focal Impaired Awareness Seizures
Get an email about SUPN's next catalysts
Track SUPERNUS PHARMACEUTICALS (SUPN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 3 past
BIS-001ER Phase 2 Est. Readout (FIAS)
Primary completion for BIS-001ER trial (NCT03474770) in Focal Impaired Awareness Seizures
SourceSPN-821 Phase 2 Est. Readout
Primary completion for SPN-821 trial (NCT07226661) in Major Depressive Disorder (MDD)
SourceSPN-817 Phase 2 Est. Readout
Estimated primary completion for SPN-817 trial (NCT06798896) in Focal Onset Seizures. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
SPN-804
Epilepsies, Partial
Oxcarbazepine XR
Partial Epilepsy
SPN-810
Attention Deficit Disorder With Hyperactivity
Brexanolone
Tinnitus
SAGE-547
Postpartum Depression
MYOBLOC
Sialorrhea
SPN-812
Attention-Deficit/Hyperactivity Disorder
apomorphine infusion
Idiopathic Parkinson's Disease
IR Viloxazine
Attention-Deficit/Hyperactivity Disorder (ADHD)
SAGE-718
Alzheimer Disease
Molindone
Impulsive Aggression Comorbid With ADHD in Children
BIS-001ER
Focal Impaired Awareness Seizures
SPN-817
Focal Onset Seizures
TPM XR
Epilepsy
SPN-821
Major Depressive Disorder (MDD)
NV-5138
Major Depressive Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPN-804 | Phase 3 | Epilepsies, Partial | - | - |
Oxcarbazepine XR | Phase 3 | Partial Epilepsy | - | - |
SPN-810 | Phase 3 | Attention Deficit Disorder With Hyperactivity | - | - |
Brexanolone | Phase 3 | Tinnitus | - | - |
SAGE-547 | Phase 3 | Postpartum Depression | - | - |
MYOBLOC | Phase 3 | Sialorrhea | - | - |
SPN-812 | Phase 3 | Attention-Deficit/Hyperactivity Disorder | - | - |
apomorphine infusion | Phase 3 | Idiopathic Parkinson's Disease | - | - |
IR Viloxazine | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | - | - |
SAGE-718 | Phase 2 | Alzheimer Disease | - | - |
Molindone | Phase 2 | Impulsive Aggression Comorbid With ADHD in Children | - | - |
BIS-001ER | Phase 2 | Focal Impaired Awareness Seizures | - | - |
SPN-817 | Phase 2 | Focal Onset Seizures | - | - |
TPM XR | Phase 2 | Epilepsy | - | - |
SPN-821 | Phase 2 | Major Depressive Disorder (MDD) | - | - |
NV-5138 | Phase 2 | Major Depressive Disorder | - | - |
Frequently asked questions
What is in SUPERNUS PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 16 drug candidates in SUPERNUS PHARMACEUTICALS, INC.'s (SUPN) pipeline across Phase 3, Phase 2. Its lead program is apomorphine infusion (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SUPERNUS PHARMACEUTICALS, INC.'s next FDA catalyst?→
SUPERNUS PHARMACEUTICALS, INC.'s (SUPN) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SUPN biotech catalysts?→
Add SUPN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SUPERNUS PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.